Related content

Efficacy and tolerability of oxaliplatin plus fluoropyrimidines in elderly patients with metastatic colorectal carcinoma: the SICOG experience

By Comella Pasquale  

Aging Health, Vol. 2, Iss. 3, 2006-06 ,pp. : 431-436

Future Medicine

Access to resources Recommend Favorite

Pharmacokinetic and Metabolism Determinants of Fluoropyrimidines and Oxaliplatin Activity in Treatment of Colorectal Patients

By  

Current Drug Metabolism, Vol. 12, Iss. 10, 2011-12 ,pp. : 918-931

Bentham Science Publishers

Access to resources Recommend Favorite

Oral fluoropyrimidines in the treatment of colorectal cancer

By Meropol N.J.  

European Journal of Cancer, Vol. 34, Iss. 10, 1998-09 ,pp. : 1509-1513

Elsevier

Access to resources Recommend Favorite

Is there a palliative benefit of gemcitabine plus fluoropyrimidines in patients with refractory colorectal cancer? A review of the literature

By Merl MY   Hoimes CJ   Pham T   Saif M Wasif  

Expert Opinion on Investigational Drugs, Vol. 18, Iss. 9, 2009-09 ,pp. : 1257-1264

Informa Healthcare

Access to resources Recommend Favorite

DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan

By  

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 80, Iss. 3, 2015-09 ,pp. : 581-588

John Wiley & Sons Inc

Access to resources Recommend Favorite